← back to search

Kanwal Raghav

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Cancer Research
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer, and Gastric Cancer Management and Outcomes.
h-index
48
citations
8,977
works
529
NIH funding
primary concept
Medicine
email

Recent publications

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
Nature Medicine 2025cited by 25position: middledoi
Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases
Annals of Surgical Oncology 2025cited by 8position: middledoi
ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Clinical Cancer Research 2025cited by 7position: middledoi
Consensus Guideline for the Management of Peritoneal Mesothelioma
Annals of Surgical Oncology 2025cited by 4position: middledoi
First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.
Journal of Clinical Oncology 2024cited by 13position: middledoi
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Clinical Cancer Research 2022cited by 29position: middledoi
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Journal of Clinical Oncology 2020cited by 390position: middledoi
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
Nature Reviews Clinical Oncology 2020cited by 365position: middledoi
CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence
EBioMedicine 2020cited by 133position: middledoi
Phase 2 study of pembrolizumab in patients with advanced rare cancers
Journal for ImmunoTherapy of Cancer 2020cited by 130position: middledoi
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
Pancreatology 2020cited by 41position: middledoi
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
The Lancet Oncology 2019cited by 561position: middledoi
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
JAMA Oncology 2019cited by 472position: middledoi
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
Annals of Oncology 2018cited by 238position: middledoi
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
Journal of Clinical Oncology 2017cited by 59position: middledoi
Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.
Journal of Clinical Oncology 2017cited by 41position: middledoi
Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
British Journal of Cancer 2015cited by 148position: middledoi
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma
Gastroenterology 2015cited by 106position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Robert A. Wolff · The University of Texas MD Anderson Cancer Center4 papers (2015–2022)Scott Kopetz · The University of Texas MD Anderson Cancer Center4 papers (2015–2020)Razelle Kurzrock · Froedtert Hospital3 papers (2017–2025)Milind Javle · The University of Texas MD Anderson Cancer Center3 papers (2019–2022)Howard A. Burris · Sarah Cannon3 papers (2017–2025)Funda Meric‐Bernstam · Breast Cancer Care3 papers (2017–2025)Ron Bose · Alvin J. Siteman Cancer Center3 papers (2017–2025)Christopher J. Sweeney · Harvard University3 papers (2017–2025)Michael J. Overman · The University of Texas MD Anderson Cancer Center3 papers (2015–2020)Van K. Morris · The University of Texas MD Anderson Cancer Center3 papers (2017–2020)Christopher H. Lieu · The University of Texas Southwestern Medical Center3 papers (2015–2020)Rachna T. Shroff · American Cancer Society3 papers (2019–2022)Charles Swanton · Cancer Evolution and Genome Instability Laboratory3 papers (2017–2025)David R. Spigel · Henan Cancer Hospital3 papers (2017–2025)David S. Hong · The University of Texas MD Anderson Cancer Center3 papers (2015–2020)Katja Schulze · La Roche College2 papers (2019–2025)Ari M. Vanderwalde · Research Network (United States)2 papers (2017–2019)Heinz‐Josef Lenz · Keck Hospital of USC2 papers (2017–2020)Ahmed O. Kaseb · The University of Texas MD Anderson Cancer Center2 papers (2015–2019)Herbert I. Hurwitz · Duke University2 papers (2017–2019)